Phase 3 Development of Resmetirom: a Liver-Directed Thyroid Hormone Receptor (THR)-Beta Agonist for the Treatment of Patients with NASH and Significant Liver Fibrosis
(as presented at EASL 2021)

Click icon in video above (bottom right) for full-screen

Collaboration Center

Please click below to view Presentations video_graphics video_graphics video_graphics video_graphics